Related Experiment Video
Updated: May 22, 2025
Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Sex Disparities in P53 Regulation and Functions: Novel Insights for Personalized Cancer Therapies
Miriana Cardano1, Giacomo Buscemi1, Laura Zannini1
1Istituto di Genetica Molecolare Luigi Luca Cavalli-Sforza, Consiglio Nazionale delle Ricerche (IGM-CNR), 20133 Pavia, Italy.
Abstract:
Epidemiological studies have revealed significant sex differences in the incidence of tumors unrelated to reproductive functions, with females demonstrating a lesser risk and a better response to therapy than males. However, the reasons for these disparities are still unknown and cancer therapies are generally sex-unbiased. The tumor-suppressor protein p53 is a transcription factor that can activate the expression of multiple target genes mainly involved in the maintenance of genome stability and tumor prevention. It is encoded by TP53, which is the most-frequently mutated gene in human cancers and therefore constitutes an attractive target for therapy. Recently, evidence of sex differences has emerged in both p53 regulations and functions, possibly providing novel opportunities for personalized cancer medicine. Here, we will review and discuss current knowledge about sexual disparities in p53 pathways, their role in tumorigenesis and cancer progression, and their importance in the therapy choice process, finally highlighting the importance of considering sex contribution in both basic research and clinical practice.
Insights
Females have a lower cancer risk and better treatment response than males due to sex differences in tumor suppressor p53 pathways. Understanding these disparities can personalize cancer medicine.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Epidemiological studies show significant sex disparities in cancer incidence and therapy response, with females generally having better outcomes.
- The tumor suppressor protein p53, encoded by the frequently mutated TP53 gene, plays a critical role in cancer prevention and genome stability.
- Current cancer therapies are largely sex-unbiased, despite emerging evidence of sex-specific p53 pathway regulation and function.
Purpose of the Study:
- To review and discuss the current knowledge on sexual disparities in p53 pathways.
- To explore the role of these disparities in tumorigenesis and cancer progression.
- To highlight the importance of considering sex in cancer research and clinical practice for personalized medicine.
Main Methods:
- Literature review and synthesis of existing research on sex differences in p53 pathways.
- Analysis of epidemiological data regarding sex-based variations in cancer incidence and treatment outcomes.
- Discussion of the implications of p53 pathway sex differences for cancer therapy.
Main Results:
- Emerging evidence indicates sex differences in the regulation and function of the p53 pathway.
- These sex-specific differences may contribute to observed disparities in cancer risk and therapy response between males and females.
- The TP53 gene and its encoded protein p53 are frequently altered in human cancers, making them a key focus.
Conclusions:
- Sexual disparities in p53 pathways offer potential for developing sex-specific, personalized cancer therapies.
- Integrating sex as a biological variable in research is crucial for advancing cancer treatment strategies.
- Further research is needed to fully elucidate and leverage these sex differences in clinical practice.
More Related Videos
Related Concept Videos
02:23Abnormal Proliferation
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
02:37DNA Damage can Stall the Cell Cycle
01:23Negative Regulator Molecules